BMO Capital analyst Brian Skorney raised the price target on Regeneron Pharma (NASDAQ: REGN) to $410.00 (from $388.00) while maintaining a Market Perform rating, saying they are incrementally positive on earnings.

Skorney commented, "Regeneron reported strong fourth quarter earnings coming in ahead of both top- and bottom-line estimates. Dupixent continued its impressive launch, and Libtayo seems to be off to a successful start as well. As a result of the strong launches of Dupixent and Libtayo we are increasing our sales estimates for these medications moving forward, and raising our price target to $410."